Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

CSPC PHARMA (01093.HK) announced that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

WuXi XDC is trading at a price-to-earnings (P/E) ratio of 32 times, a significant premium over WuXi AppTec's 14 times.